Trial document

This study has been imported from without additional data checks.
drksid header


Trial Description

start of 1:1-Block title


Neoadjuvant Chemotherapy With Cabazitaxel in High Risk Prostate Cancer Patients Prior to Radical Prostatectomy

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym


end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial


end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

This study is aimed at evaluating the efficacy regarding the response rate and
metastasis-free survival time of cabazitaxel as a neoadjuvant treatment in patients with
high risk prostate cancer.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

Patients will be treated by 6 cycles of Cabazitaxel 25 mg/m2 every three weeks and extended
radical prostatectomy and extended pelvic lymphadenectomy 4 weeks after completion of
chemotherapy. Multiparametric MRI will be performed at baseline, after 3 cycles and after 6
cycles. If there will be evidence of clinical progression after 3rd cycle, patients can be
removed from the study and given local therapy, including radical prostatectomy or external
beam radiotherapy, at the discretion of the patient's physicians. If patients have evidence
of response, they continue on treatment for a total of 6 cycles. If multiparametric MRI
demonstrates stable disease an individual risk-benefit analysis has to be performed with
regard to continuing or to stopping the neoadjuvant treatment since the definition stable
disease includes patients with ≤ 20% tumour shrinkage or tumour progression

end of 1:1-Block scientific synopsis
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00006362
  •   2014/09/03
  •   2013/07/22
  •   yes
  •   [---]*
  •   [---]*
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  •   NCT01941550  (
  •   13-005  (RWTH Aachen University)
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   High-Risk Cancer
  •   C61 -  Malignant neoplasm of prostate
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   Drug: Cabazitaxel chemotherapy
end of 1:N-Block interventions
start of 1:1-Block design


  •   Interventional
  •   [---]*
  •   Single arm study
  •   Open (masking not used)
  •   [---]*
  •   Uncontrolled/Single arm
  •   Treatment
  •   Single (group)
  •   II
  •   [---]*
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

- Complete pathological response rate; time frame: 5 years; Primary endpoint: overall or cancer specific survival nor progression-free survival(PFS) in 5 years. Composite measurement.
Complete pathohistological remission
Intra/perioperative compl.
Biochemical, radiological, clinical PFS and androgen-deprivation FS
Objective progr. during cabazitaxel therapy ( and post surgery
PSA response at the end of
PSA progression after 12 w. of
Percentage of pat. with undetectable PSA (<0.1 ng/ml) post surgery
Relationship between PSA kinetics, histol. response and MRI response
Role of pathohistol. parameters such as intraductal, cribriform growth patterns and effect on response
Immunohistochemical evaluation of prostate biopsy and radical prostatectomy specimens of markers potentially associated with chemoresistance: growth differentiation factor 15, surviving, beta-tubuline I & II, p53, bcl-2,
Measurement of the serum concentrations of free circulating mDNA

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome


end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Germany
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

end of 1:n-Block recruitment locations
start of 1:1-Block recruitment


  •   [---]*
  •   2013/07/31
  •   35
  •   [---]*
  •   [---]*
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Male
  •   18   Years
  •   no maximum age
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

- Surgically resectable high risk prostate cancer with a 5-year relapse probability ≥
60% according to the Kattan pre-operative nomogram (cancer 2009, 115: 1005-1010)

- no prior therapy for prostate cancer such as androgen deprivation therapy,
radiation therapy, or chemotherapy

- ECOG performance status 0-1

- No evidence of active infection

- Hemoglobin >9.0 g/dL

- Absolute neutrophil count >1.5 x 109/L,

- Platelet count >100 x 109/L,

- AST/SGOT and/or ALT/SGPT <2.5 x ULN;

- Total bilirubin <1.0 x ULN,

- Serum creatinine <1.5 x ULN. If creatinine 1.0 - 1.5 x ULN, creatinine clearance
will be calculated according to CKD-EPI formula and patients with creatinine
clearance <60 mL/min should be excluded)

- Patient information and signature of informed consent

- Male ≥ 18 years

- Patients of reproductive age must take appropriate contraceptive precautions
during and for 6 months after the end of their participation in the study

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

- Evidence of lymph node, visceral or bone metastases

- previous major intrapelvic surgery

- previous radiation therapy to the small pelvis

- any type of malignancies within the last 5 years except basalioma and non-muscle
invasive urothelial cancer of the urinary bladder

- previous chemotherapy with taxanes (docetaxel, paclitaxel, cabazitaxel) for any

- Hypersensitivity to the active substance or to any of the excipients

- Known or suspected brain metastases or leptomeningeal metastases

- Active or symptomatic viral hepatitis or chronic liver disease

- Serious or uncontrolled co-existent non-malignant disease, including active and
uncontrolled infection

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses


  • start of 1:1-Block address primary-sponsor
    • RWTH Aachen University
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address scientific-contact
    • Department of Urology
    • Axel Heidenreich, Prof. 
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • Department of Urology
    • Axel Heidenreich, Prof. 
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state


  •   Recruiting suspended on temporary hold
  •   [---]*
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  • [---]*
end of 1:n-Block publications
The parameters in and DRKS are not identical. Therefore the data import from required adjustments. For full details please see the DRKS FAQs .
  •   4
  •   2016/01/14

* This entry means the parameter is not applicable or has not been set.